...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Internal medicine. >Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study
【24h】

Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study

机译：每日两次雷贝拉唑对难治性反流性食管炎患者健康相关生活质量和症状的治疗反应：多中心观察性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Objective To investigate the effect of twice-daily rabeprazole doses on health-related quality of life in refractory patients. Methods and Patients Reflux esophagitis patients with an insufficient response to once-daily proton pump inhibitor therapy (Los Angeles Classification grade A-D) received rabeprazole 10 mg or 20 mg twice daily for 8 weeks. The health-related quality of life (SF-8?) and symptoms, using the Frequency Scale for the Symptoms of Gastroesophageal reflux disease, were evaluated before treatment and at weeks 4 and 8. Endoscopy was performed at baseline and at weeks 8 and 32 where possible. The rabeprazole dose was determined by the attending physician. Results There were 1,796 patients analyzed for the efficacy of the twice-daily treatment. Of these cases, 1,462 were treated with rabeprazole 10 mg twice daily, and 334 were treated with rabeprazole 20 mg twice daily. The factors that affected the selection of the twice-daily rabeprazole dose by physicians were evaluated, and as expected, "endoscopic findings when treatment was started" had a strong effect on the selection of the rabeprazole dose. With both regimens, health-related quality of life and subjective symptoms were significantly improved at weeks 4 and 8 compared to baseline (p Conclusion Twice-daily treatment with rabeprazole improved the subjective symptoms and health-related quality of life in patients with refractory reflux esophagitis more effectively than the standard once-daily dose.
机译：目的探讨雷贝拉唑的每日两次剂量对难治性患者健康相关生活质量的影响。方法和患者对每日一次的质子泵抑制剂治疗（洛杉矶分类A-D）反应不佳的反流性食管炎患者接受雷贝拉唑10 mg或20 mg每天两次，共8周。使用胃食管反流疾病症状频率量表对健康相关的生活质量（SF-8？）和症状进行了评估，然后进行治疗前以及第4周和第8周的评估。在基线以及第8周和第32周进行了内镜检查。在可能的情况。雷贝拉唑的剂量由主治医生确定。结果分析了每天1次治疗的1,796例患者的疗效。在这些病例中，有1,462例接受雷贝拉唑10 mg每天两次治疗，334例接受雷贝拉唑20 mg每天两次治疗。评估了影响医生选择每日两次雷贝拉唑剂量的因素，并且正如预期的那样，“开始治疗时的内镜检查结果”对雷贝拉唑剂量的选择产生了强烈影响。与基线相比，两种治疗方案在第4周和第8周时与健康相关的生活质量和主观症状均得到显着改善（p结论每天两次雷贝拉唑治疗可改善难治性反流性食管炎患者的主观症状和与健康相关的生活质量。比标准的每日一次剂量更有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号